PT  - JOURNAL ARTICLE
AU  - Dmitry V. Zaretsky
AU  - Maria V. Zaretskaia
AU  - Yaroslav I. Molkov
AU  - for the Alzheimer’s Disease Neuroimaging Initiative
TI  - Patients with Alzheimer’s disease have increased cellular amyloid uptake
AID  - 10.1101/2022.01.12.22269196
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.12.22269196
4099  - http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269196.short
4100  - http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269196.full
AB  - Amyloid plaques are the main signature of Alzheimer’s disease (AD). Beta-amyloid (Aβ) concentration in cerebrospinal fluid (CSF-Aβ) and the density of amyloid depositions have a strong negative correlation. However, AD patients have lower CSF-Aβ levels compared to cognitively normal people even after accounting for this correlation. The goal of this study was to infer variations of parameters in Aβ metabolism of AD patients that underlie this difference using data from the Alzheimer’s Disease Neuroimaging Initiative cohort.We found that AD patients had dramatically increased rates of cellular amyloid uptake compared to individuals with normal cognition (NC). A group with late-onset mild cognitive impairment (LMCI) also exhibited stronger amyloid uptake, however this was less pronounced than in the AD group. Estimated parameters in the early-onset MCI group did not differ significantly from those in the NC group.Aβ cytotoxicity depends on both the amount of peptide internalized by cells and its intracellular degradation into toxic products. Based on our results, we speculate that AD and LMCI are associated with increased cellular amyloid uptake which leads to faster disease progression, whereas the early-onset MCI may be mediated by the increased production of toxic amyloid metabolites.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttp://adni.loni.usc.edu/about/Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from ADNI.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors http://adni.loni.usc.edu/about/ ADAlzheimer’s diseaseMCImild cognitive impairmentLMCIlate-onset MCIEMCIearlyonset MCINCnormal cognitionAβbeta-amyloidAβ42Aβ1-42CSFcerebrospinal fluidCSF-Aβ42concentration of Aβ42 in the CSF